Description
Fumagillin is an antimicrobial compound initially produced by species of Aspergillus that exhibits anti-parasitic, antimalarial, anti-fibrotic, anti-angiogenic, and anticancer chemotherapeutic activities. Fumagillin is clinically used to treat microsporidiosis and displays efficacy against Plasmodium, Nosema, and Enterocytozoon. In vivo, fumagillin decreases pulmonary fibrosis, pulmonary hypertension, and ventricular remodeling. In cellular and animal models of colorectal cancer, fumagillin inhibits type 2 methionine aminopeptidase, preventing tube and vessel formation and well as cell proliferation, migration, and adhesion; it also decreases tumor mass.
References
Kass DJ, Rattigan E, Kahloon R, et al. Early treatment with fumagillin, an inhibitor of methionine aminopeptidase-2, prevents Pulmonary Hypertension in monocrotaline-injured rats. PLoS One. 2012;7(4):e35388. PMID: 22509410.
Champion L, Durrbach A, Lang P, et al. Fumagillin for treatment of intestinal microsporidiosis in renal transplant recipients. Am J Transplant. 2010 Aug;10(8):1925-30. PMID: 20636462.
Arico-Muendel C, Centrella PA, Contonio BD, et al. Antiparasitic activities of novel, orally available fumagillin analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5128-31. PMID: 19648008.
Hou L, Mori D, Takase Y, et al. Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis. Pathol Int. 2009 Jul;59(7):448-61. PMID: 19563408.
Chen X, Xie S, Bhat S, et al. Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo. Chem Biol. 2009 Feb 27;16(2):193-202. PMID: 19246010.
